ArticleNeuromolecular medicine2026
Exosomal miR-1278 From Bone Marrow Mesenchymal Stem Cells Modulates Ldha-Mediated Microglia Polarization to Decelerate Parkinson's Disease Pathology.
Article in Neuromolecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease, which can’t be cured at present. Bone marrow mesenchymal stem cells (BMSCs)-derived exosomal microRNAs are involved in various neurodegenerative diseases. While BMSC-derived exosomes show therapeutic potential in PD, their specific mechanisms remain elusive. This research aims to elucidate the functional mechanism of exosomal miR-1278 from BMSCs in PD. The motor deficits and cognitive function of mice were assessed by Pole test, Rotarod test, Open field test, and Morris water maze. Western blotting assay and qRT-PCR were carried out to evaluate gene and miRNA expressions. Neuronal apoptosis was elevated by TUNEL assay. Immunofluorescence staining assessed microglial activation. Flow cytometry assay was conducted to detect microglia apoptosis and polarization. Inflammatory cytokines levels were measured by ELISA. Metabolic assays included Seahorse ECAR/OCR, FAO, and lactic acid quantification. BMSCs can improve the motor and cognitive deficits of PD mice by relieving neuronal damage and microglia-induced neuroinflammation. As for the molecular mechanism, downregulation of miR-1278 was identified in plasma exosomes and BMSCs from PD patients. And exosomes can transfer miR-1278 from BMSCs to microglia. Exosomal miR-1278 alleviated apoptosis and M1 polarization of microglia. Further, miR-1278 targets LDHA and downregulates its expression microglia. LDHA knockdown promoted M2 polarization and prevented apoptosis of microglia by impairing glycolysis and enhancing fatty acid oxidation (FAO). In vivo assay also demonstrated that BMSCs-derived miR-1278 relieved motor and cognitive deficits in PD mice through regulating LDHA-mediated polarization of microglia. Exosomal miR-1278 from BMSCs promotes M2 polarization of microglia by regulating LDHA-mediated metabolism reprogramming, thereby relieving neuronal damage and neuroinflammation in PD. This study elucidates a novel mechanistic pathway involving miR-1278/LDHA, offering a precise target for future PD therapies.
Indexed as
Identifiers
42026401What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.